中国医药科学2024，Vol.14Issue(12)：13-16,4.DOI:10.20116/j.issn2095-0616.2024.12.03
三七治疗肺癌作用机制的网络药理学研究与分子对接技术的验证
Network pharmacological study on the mechanism of Panax notoginseng in treating lung cancer and verification of molecular docking technology
摘要
Abstract
Objective To study the mechanism of Panax notoginseng in treating lung cancer based on network pharmacology and validate it through molecular docking.Methods The active ingredients and targets of Panax notoginseng were inquired from the pharmacology database and analysis platform of traditional Chinese medicine system(TCMSP),and the targets of lung cancer were inquired from the DisGeNET database.Protein-protein interaction(PPI)network analysis and enrichment analysis were carried out on the intersection of drug action targets and disease targets.The ingredients and targets of Panax notoginseng were molecularly docked and visually displayed.Results Eight active ingredients of Panax notoginseng,including quercetin and ginsenoside rh2,were screened out,and there were 182 corresponding targets.There were 266 lung cancer-related 38 repeated targets of drugs and diseases.PPI network analysis showed that tumor protein P53(TP53),estrogen receptor 1(ESR1),protein kinase(AKT1)and MYC proto-oncogene may be the core targets of Panax notoginseng in treating lung cancer.The core ingredients of Panax notoginseng had good binding activity with the above-mentioned core targets.Gene ontolory enrichment analysis and Kyoto encyclopedia of genes and genomes pathway enrichment analysis showed that Panax notoginseng played a therapeutic role in lung cancer through 345 Gene ontolory terms and 134 pathways.Conclusion Panax notoginseng plays a therapeutic role in lung cancer through multiple active ingredients,multiple targets,and multiple pathways.关键词
网络药理学/分子对接/三七/肺癌/作用机制Key words
Network pharmacology/Molecular docking/Panax notoginseng/Lung cancer/Mechanism of action分类
医药卫生引用本文复制引用
林静,王辉,吕灵通..三七治疗肺癌作用机制的网络药理学研究与分子对接技术的验证[J].中国医药科学,2024,14(12):13-16,4.基金项目
济南市卫生健康委员会科技计划项目(2023-中-58). （2023-中-58）
